4Moving Biotech forms its Scientific Advisory Board of World-Renowned Knee Osteoarthritis Experts
4Moving Biotech, a subsidiary of 4P-Pharma, announces establishing an international Scientific Advisory Board in anticipation of its knee osteoarthritis drug candidate's phase 2b clinical trial.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231110575256/en/
(Graphic: Business Wire)
This board, composed of eminent international experts, will play a key role in supporting the development of 4P004, our drug candidate, to address the current gap in curative treatment for knee osteoarthritis.
The expertise of this committee will reinforce our scientific approach based on intraarticular GLP-1 analogs and will advise us on the best regulatory path.
Professor Francis Berenbaum, CMO of 4Moving Biotech, will lead the work of this scientific advisory board.
He will be joined by renowned medical experts, including:
- Philip Conaghan: Professor of Musculoskeletal Medicine, University of Leeds and Director, NIHR Leeds Biomedical Research Centre, United Kingdom.
- Felix Eckstein: Head of the Department for Imaging and Functional Musculoskeletal Research, Institute of Anatomy and Cell Biology, Paracelsus Medical University, Salzburg, Austria, and Chondrometrics GmbH, Freilassing.
- Ali Guermazi: Professor of Radiology and Medicine at Boston University School of Medicine, Boston, United States.
- Changqing Zhang: Director of the National Center for Orthopedics, Head of the Department of Orthopedic Surgery at the Sixth People's Hospital, Director of Shanghai Institute of Microsurgery, Shanghai, China. He will be supported by Yanyan Song: Associate Professor in the Department of Biostatistics at the Institute of Clinical Research, Faculty of Medicine, Jiao-Tong University and Hongyi ZHU: Specialized Orthopedic Surgeon and Microsurgeon.
The Scientific Advisory Board will bring deep knowledge and experience from clinical research, academia, and industry to better serve people suffering from knee osteoarthritis.
“It is an honor to chair a scientific advisory board of such key opinion leaders. Establishing this committee adds fantastic scientific and medical values to our clinical research program.” stated Professor Francis Berenbaum, CMO of 4Moving Biotech.
Innovation for knee osteoarthritis with a first-in-class therapeutic target
Knee osteoarthritis affects more than 300 million people worldwide1. There is currently no curative treatment. 4Moving Biotech has responded to this challenge with an innovative research program to explore the potential of intra-articular GLP-1 analogs for knee osteoarthritis treatment.
"With their expertise in clinical study design and regulatory affairs, this high-level scientific advisory board will greatly contribute to the future success of 4P004, reinforcing our pioneering position in developing advanced therapeutic solutions," concluded Revital Rattenbach, Chairwoman of 4Moving Biotech.
The Phase 2b clinical trial with 4P004 will represent a key milestone for the company in its pursuit of seeking approval for its knee osteoarthritis drug candidate.
About 4Moving Biotech
4Moving Biotech is a biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD) candidate 4P004. Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis.
4Moving Biotech was founded in July 2020 and is a majority-owned subsidiary of 4P-Pharma. The company is headquartered at the Pasteur Institute in Lille, France.
Site internet : https://www.4movingbiotech.com/
The version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Jean-Raymond Dadjé – emmanuel.dadje@4P-Pharma.com
06 30 06 12 13
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Evolito First in UK to Secure CAA Design Organisation Approval for Electric Propulsion Systems5.12.2023 09:00:00 CET | Press release
Evolito Limited, the pioneer of world-leading axial-flux electric motors, power electronics and battery solutions for aerospace applications, has received Design Organisation Approval (DOA) from the UK Civil Aviation Authority for electric propulsion system products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231201483295/en/ Evolito’s D500 Axial Flux Motor: stacked for increased torque and power up to 1 megawatt. (Photo: Business Wire) The UK Civil Aviation Authority’s approval of Evolito as a Design Organisation demonstrates that it is satisfied that Evolito has the technical expertise, facilities and capabilities to design safe and reliable products, and is able to comply with stringent requirements for certification. Evolito is the first company in the UK to achieve this for electric propulsion systems. This accreditation is a significant milestone towards certification of Evolito’s products, as well as supporting cu
PUMA Scale-up Their Textile-to-textile Recycling Technology, Creating All Future Replica Football Kit Using RE:FIBRE Technology5.12.2023 09:00:00 CET | Press release
Global sports company PUMA has today announced that it has scaled up its textile recycling innovation, RE:FIBRE, replacing recycled polyester with RE:FIBRE technology in all PUMA football Club and Federation replica jerseys from 2024 onwards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205250478/en/ Global sports company PUMA has today announced that it has scaled up its textile recycling innovation, RE:FIBRE, replacing recycled polyester with RE:FIBRE technology in all PUMA football Club and Federation replica jerseys from 2024 onwards. (Photo: Business Wire) Since the launch of the pilot in 2022, which saw PUMA produce recycled training jerseys for their sponsored football clubs, RE:FIBRE technology has been used to create Switzerland and Morocco replica kits for the Women’s World Cup as well as Girona’s 2023/24 season Third kit. In 2024, official PUMA football replica jerseys* including those for the Euro and Copa A
Taulia Adds Bank of China and BNP Paribas to Its Funder Network5.12.2023 09:00:00 CET | Press release
Taulia, a leading provider of working capital management solutions, today announced it has added the Bank of China London Branch, and BNP Paribas to its global multi-funder network. The addition of the two major global banks is the most recent in an already large and growing network of funders available to Taulia’s global customers, enabling businesses to access an increasingly broad and diverse funding pool, with greater choice, liquidity, and availability of capital. Multifunder models within supply chain finance programs are designed to provide resilience through diversification and a wider pool of funding for different currencies, geographies, client sizes, and credit profiles. Combined with the right technology, it also enables businesses to hedge against liquidity risk, particularly during periods of economic uncertainty. Cedric Bru, CEO, Taulia, comments: “Adding Bank of China and BNP Paribas to the Taulia multi-funder network is an enormous achievement, and we are delighted to
FPT Software Joins Global Tech Giants in the AI Alliance as Founding Member5.12.2023 07:00:00 CET | Press release
FPT Software, a global leading IT provider, announced its participation in the AIAlliance, a pivotal initiative formed by leading organizations across industry, startup, academia, research, and government with a shared goal of supporting open innovation and open science in AI. The alliance is expected to advance AI collaboration and foster innovation across all aspects of AI technology, applications, and governance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231204440838/en/ FPT Software Participates in the AI Alliance with Other Global Tech Giants (Photo: Business Wire) The Alliance, co-launched by IBM and Meta in collaboration with Founding Members globally, aims to leverage a critical mass of computing, data, tools, and talent to accelerate open innovation in AI to build and support open technologies across software, models, and tools, which empower students, developers, and scientists to understand and embrace open t
Wallarm Reveals Current Threats to API Security, Move to 100% Channel Strategy and New API Attack Management Solution at Black Hat Europe 20235.12.2023 07:00:00 CET | Press release
BLACK HAT EUROPE 2023 –Wallarm, the integrated app and API security company, today announced its upcoming appearance at Black Hat Europe 2023, the Dec. 4 to Dec. 7 conference that provides the latest in research, development and trends in information security. Wallarm executives are hosting a session on Dec. 7 at 12:15 p.m. GMT at ExCeL London and sharing critical insights and recommendations from the latest API ThreatStats™ report. Additionally, Wallarm is discussing its new 100% channel strategy and launching a new API Attack Surface Management solution during Black Hat Europe. Wallarm’s Black Hat appearance comes as interest in API security solutions grows in Europe, with the Europe API security market expected to witness market growth of 31.5% CAGR during the forecast period (2023-2030). This critical opportunity allows Wallarm to build awareness around the need for API and app security, jump-start expansion to the European market and recruit additional channel partners. Key announ